Composition: Butenafine HCl 1%.

Indications: Butenafine cream is indicated for the topical treatment of following superficial dermatophytes: tinea pedis (athletes foot), tinea corporis (ringworm), tinea cruris (jockitch) due to M. furfur, E. floccosum, T. mentagrophytes, T. rubrum, T. tonsurans.

Dosage and administration: Patients with tinea (pityriasis) versicolor should apply butenafine once daily for two weeks. In the treatment of interdigital tinea pedis butenafine should be applied twice daily for 7 days or once daily for 4 weeks. Patients with tinea corporis or tinea cruris should apply butenafine once daily for two weeks. Or, as directed by the registered physician.

Contraindication: It is contraindicated in those patients who are hypersensitive to butenafine.

Side effects: The most frequently reported adverse events in patients treated with butenafine cream, contact dermatitis, erythema, irritation and itching.

Precautions: Butenafine HCI cream is not for ophthalmic, oral or intravaginal use. Use, as directed by the physician and avoid contact with the eyes and mouth and other mucous membranes.

Fintop Cream

Use in Pregnancy and lactation: No adequate and well controlled studies that have been conducted with topically applied butenafine in pregnant women. This drug should be used during pregnancy only if clearly needed. It is not known if butenafine HCl is excreted in human milk, caution should be exercised in prescribing butenafine Cream, to a nursing woman. Pregnancy Category C.

Drug interactions : Potential drug interactions between butenafine HCl cream and other drug have not been evaluated.

Packing: Fintop Cream: 10gm in a tube.